Clinical Significance of Adverse Events for Patients with Unresectable Hepatocellular Carcinoma Treated with Lenvatinib: A Multicenter Retrospective Study

Clinical Significance of Adverse Events for Patients with Unresectable Hepatocellular Carcinoma Treated with Lenvatinib: A Multicenter Retrospective Study

We sought to investigate the clinical profile(s) associated with the discontinuation of lenvatinib (LEN) due to severe adverse events (DLSAE) in patients with unresectable hepatocellular carcinoma (HCC). This retrospective study enrolled 177 patients with HCC treated with LEN. Independent factors as...

Full description

Bibliographic Details
Main Authors: Shigeo Shimose, Hideki Iwamoto, Takashi Niizeki, Tomotake Shirono, Yu Noda, Naoki Kamachi, Shusuke Okamura, Masahito Nakano, Hideya Suga, Ryoko Kuromatsu, Taizo Yamaguchi, Takumi Kawaguchi, Masatoshi Tanaka, Kazunori Noguchi, Hironori Koga, Takuji Torimura
Format: Article
Language:English
Published: MDPI AG 2020-07-01
Series:Cancers
Subjects:
lenvatinib
adverse events
molecular target agents
hepatocellular carcinoma
Online Access:https://www.mdpi.com/2072-6694/12/7/1867

Internet

https://www.mdpi.com/2072-6694/12/7/1867

Similar Items